| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 223 | 2024 | 5752 | 11.210 |
Why?
|
| Graft vs Host Disease | 194 | 2024 | 3079 | 10.930 |
Why?
|
| Transplantation Conditioning | 92 | 2024 | 1635 | 6.080 |
Why?
|
| Leukemia, Myeloid, Acute | 59 | 2025 | 3637 | 4.440 |
Why?
|
| Transplantation, Homologous | 156 | 2024 | 4859 | 4.210 |
Why?
|
| Hepatic Veno-Occlusive Disease | 22 | 2022 | 221 | 3.490 |
Why?
|
| Bone Marrow Transplantation | 93 | 2023 | 2729 | 3.480 |
Why?
|
| Lymphocyte Depletion | 35 | 2022 | 606 | 3.270 |
Why?
|
| Myelodysplastic Syndromes | 31 | 2024 | 1404 | 3.250 |
Why?
|
| Hematologic Neoplasms | 63 | 2022 | 1926 | 3.030 |
Why?
|
| Polydeoxyribonucleotides | 14 | 2022 | 136 | 2.370 |
Why?
|
| Interleukin-2 | 28 | 2022 | 1894 | 2.000 |
Why?
|
| Leukemia | 28 | 2024 | 1522 | 1.980 |
Why?
|
| Lymphocyte Transfusion | 24 | 2021 | 236 | 1.960 |
Why?
|
| Cord Blood Stem Cell Transplantation | 22 | 2019 | 316 | 1.840 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 17 | 2016 | 266 | 1.780 |
Why?
|
| Tacrolimus | 22 | 2023 | 754 | 1.640 |
Why?
|
| Antilymphocyte Serum | 7 | 2018 | 492 | 1.460 |
Why?
|
| T-Lymphocytes | 48 | 2022 | 10256 | 1.410 |
Why?
|
| Recurrence | 66 | 2023 | 8492 | 1.320 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 28 | 2013 | 685 | 1.320 |
Why?
|
| Immunosuppressive Agents | 29 | 2021 | 4213 | 1.190 |
Why?
|
| Lymphoma, Non-Hodgkin | 20 | 2021 | 1374 | 1.110 |
Why?
|
| Graft vs Leukemia Effect | 13 | 2024 | 122 | 1.090 |
Why?
|
| Stem Cell Transplantation | 24 | 2023 | 1600 | 1.060 |
Why?
|
| Cyclophosphamide | 28 | 2023 | 2232 | 1.050 |
Why?
|
| Myeloablative Agonists | 16 | 2021 | 215 | 1.050 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 6 | 2024 | 496 | 1.010 |
Why?
|
| T-Lymphocytes, Regulatory | 23 | 2022 | 3111 | 1.000 |
Why?
|
| Sirolimus | 16 | 2020 | 1541 | 1.000 |
Why?
|
| Killer Cells, Natural | 18 | 2024 | 2206 | 0.930 |
Why?
|
| Disease-Free Survival | 50 | 2021 | 6838 | 0.920 |
Why?
|
| Adult | 292 | 2024 | 223088 | 0.910 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 14 | 2023 | 890 | 0.890 |
Why?
|
| Middle Aged | 285 | 2025 | 223016 | 0.880 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 14 | 2022 | 893 | 0.870 |
Why?
|
| Leukemia, Myeloid | 8 | 2021 | 695 | 0.850 |
Why?
|
| Busulfan | 13 | 2021 | 264 | 0.820 |
Why?
|
| Transplantation, Autologous | 39 | 2023 | 2125 | 0.810 |
Why?
|
| Lymphoma | 13 | 2021 | 1896 | 0.800 |
Why?
|
| Mouth Diseases | 5 | 2018 | 239 | 0.800 |
Why?
|
| Humans | 443 | 2025 | 765926 | 0.790 |
Why?
|
| Survival Analysis | 53 | 2018 | 10086 | 0.780 |
Why?
|
| Whole-Body Irradiation | 17 | 2019 | 438 | 0.780 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 11 | 2017 | 1559 | 0.770 |
Why?
|
| Antigens, CD | 27 | 2022 | 4023 | 0.770 |
Why?
|
| Multiple Organ Failure | 10 | 2021 | 389 | 0.770 |
Why?
|
| Antigens, CD34 | 6 | 2024 | 656 | 0.760 |
Why?
|
| Chronic Disease | 48 | 2023 | 9351 | 0.750 |
Why?
|
| Azithromycin | 1 | 2022 | 202 | 0.740 |
Why?
|
| Aged | 184 | 2024 | 171163 | 0.740 |
Why?
|
| Antibodies, Monoclonal | 30 | 2022 | 9239 | 0.720 |
Why?
|
| Male | 298 | 2025 | 363815 | 0.710 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 30 | 2023 | 11858 | 0.710 |
Why?
|
| CD8-Positive T-Lymphocytes | 24 | 2024 | 4641 | 0.690 |
Why?
|
| Female | 300 | 2025 | 396141 | 0.680 |
Why?
|
| Vidarabine | 15 | 2021 | 343 | 0.680 |
Why?
|
| Cancer Vaccines | 10 | 2014 | 1042 | 0.660 |
Why?
|
| Methotrexate | 17 | 2021 | 1719 | 0.660 |
Why?
|
| Multiple Myeloma | 19 | 2023 | 5189 | 0.640 |
Why?
|
| Bronchiolitis Obliterans | 6 | 2022 | 221 | 0.630 |
Why?
|
| Hematologic Diseases | 7 | 2018 | 500 | 0.610 |
Why?
|
| Globulins | 1 | 2018 | 19 | 0.600 |
Why?
|
| HLA Antigens | 14 | 2020 | 1338 | 0.590 |
Why?
|
| Survival Rate | 43 | 2021 | 12822 | 0.570 |
Why?
|
| Interleukin-15 | 1 | 2018 | 186 | 0.570 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 13 | 2021 | 1643 | 0.560 |
Why?
|
| Tissue Donors | 25 | 2024 | 2392 | 0.540 |
Why?
|
| Acute Disease | 30 | 2020 | 7236 | 0.530 |
Why?
|
| Fibrinolytic Agents | 7 | 2020 | 2076 | 0.530 |
Why?
|
| T-Lymphocyte Subsets | 7 | 2016 | 1812 | 0.530 |
Why?
|
| Diarrhea | 3 | 2021 | 1315 | 0.520 |
Why?
|
| CD4-Positive T-Lymphocytes | 25 | 2020 | 4405 | 0.520 |
Why?
|
| Young Adult | 78 | 2024 | 59857 | 0.510 |
Why?
|
| Niacinamide | 2 | 2016 | 419 | 0.510 |
Why?
|
| Remission Induction | 23 | 2019 | 2413 | 0.510 |
Why?
|
| Dexamethasone | 5 | 2023 | 1962 | 0.490 |
Why?
|
| Treatment Outcome | 91 | 2021 | 65194 | 0.490 |
Why?
|
| Cytomegalovirus Infections | 6 | 2023 | 837 | 0.480 |
Why?
|
| Transplantation Chimera | 13 | 2024 | 609 | 0.480 |
Why?
|
| Histocompatibility | 5 | 2012 | 327 | 0.480 |
Why?
|
| Mouth Neoplasms | 2 | 2018 | 594 | 0.470 |
Why?
|
| Phenylurea Compounds | 2 | 2016 | 536 | 0.470 |
Why?
|
| B-Lymphocytes | 19 | 2022 | 4782 | 0.460 |
Why?
|
| Antineoplastic Agents | 20 | 2023 | 13631 | 0.460 |
Why?
|
| Ultraviolet Therapy | 1 | 2014 | 81 | 0.460 |
Why?
|
| Pyrazines | 5 | 2024 | 1204 | 0.460 |
Why?
|
| Cytogenetic Analysis | 4 | 2009 | 270 | 0.450 |
Why?
|
| Retrospective Studies | 89 | 2024 | 81537 | 0.450 |
Why?
|
| Graft vs Tumor Effect | 7 | 2016 | 70 | 0.440 |
Why?
|
| Adolescent | 80 | 2024 | 88811 | 0.440 |
Why?
|
| Fetal Blood | 9 | 2018 | 1365 | 0.430 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2024 | 5691 | 0.430 |
Why?
|
| Combined Modality Therapy | 25 | 2021 | 8522 | 0.410 |
Why?
|
| Immunotherapy, Adoptive | 7 | 2024 | 1504 | 0.400 |
Why?
|
| Histocompatibility Testing | 13 | 2016 | 726 | 0.390 |
Why?
|
| Antibodies | 6 | 2017 | 2415 | 0.390 |
Why?
|
| Mutagenesis, Insertional | 1 | 2014 | 662 | 0.380 |
Why?
|
| Germinal Center | 3 | 2022 | 379 | 0.380 |
Why?
|
| Hypercholesterolemia | 2 | 2011 | 1148 | 0.370 |
Why?
|
| Cytomegalovirus | 4 | 2021 | 753 | 0.370 |
Why?
|
| Lymphocyte Activation | 19 | 2022 | 5500 | 0.360 |
Why?
|
| Bone Marrow Purging | 7 | 1998 | 108 | 0.360 |
Why?
|
| Survivors | 3 | 2018 | 2373 | 0.360 |
Why?
|
| Thrombotic Microangiopathies | 3 | 2022 | 125 | 0.360 |
Why?
|
| Graft Survival | 20 | 2017 | 3904 | 0.360 |
Why?
|
| Immunologic Memory | 7 | 2024 | 1374 | 0.350 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 3 | 2017 | 227 | 0.350 |
Why?
|
| Hematopoietic Stem Cells | 7 | 2017 | 3405 | 0.350 |
Why?
|
| Prognosis | 43 | 2022 | 29890 | 0.340 |
Why?
|
| Erythema | 2 | 2010 | 261 | 0.340 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2016 | 1852 | 0.330 |
Why?
|
| Cytogenetics | 2 | 2007 | 197 | 0.320 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2011 | 423 | 0.320 |
Why?
|
| Immunoglobulin G | 9 | 2023 | 4555 | 0.320 |
Why?
|
| Siblings | 2 | 2012 | 828 | 0.320 |
Why?
|
| Aniline Compounds | 2 | 2024 | 1076 | 0.310 |
Why?
|
| Quality of Life | 12 | 2024 | 13463 | 0.310 |
Why?
|
| B-Cell Activating Factor | 5 | 2014 | 115 | 0.310 |
Why?
|
| Geriatric Assessment | 3 | 2022 | 1422 | 0.300 |
Why?
|
| Hypertriglyceridemia | 1 | 2011 | 292 | 0.300 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 5 | 2016 | 633 | 0.300 |
Why?
|
| Time Factors | 37 | 2021 | 40097 | 0.290 |
Why?
|
| Pulmonary Edema | 1 | 2010 | 409 | 0.290 |
Why?
|
| Drug Interactions | 2 | 2011 | 1416 | 0.290 |
Why?
|
| Antibodies, Neoplasm | 6 | 2010 | 282 | 0.280 |
Why?
|
| Follow-Up Studies | 37 | 2021 | 39228 | 0.280 |
Why?
|
| Lymphocytes | 7 | 2014 | 2601 | 0.280 |
Why?
|
| Pyrimidines | 6 | 2015 | 3049 | 0.280 |
Why?
|
| Mutation | 17 | 2024 | 30192 | 0.280 |
Why?
|
| Lymphocyte Count | 7 | 2019 | 791 | 0.280 |
Why?
|
| Immunotherapy | 7 | 2025 | 4746 | 0.280 |
Why?
|
| Hypolipidemic Agents | 1 | 2011 | 609 | 0.270 |
Why?
|
| Fever | 3 | 2016 | 1607 | 0.270 |
Why?
|
| Myeloproliferative Disorders | 4 | 2022 | 615 | 0.270 |
Why?
|
| Steroids | 9 | 2023 | 934 | 0.270 |
Why?
|
| Antigens, Surface | 5 | 2017 | 1616 | 0.270 |
Why?
|
| Opportunistic Infections | 2 | 2023 | 376 | 0.270 |
Why?
|
| Incidence | 28 | 2023 | 21513 | 0.260 |
Why?
|
| Immunologic Factors | 2 | 2014 | 1590 | 0.260 |
Why?
|
| Endpoint Determination | 1 | 2009 | 591 | 0.260 |
Why?
|
| Piperazines | 5 | 2016 | 2546 | 0.260 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2020 | 1881 | 0.260 |
Why?
|
| Iron Overload | 4 | 2012 | 245 | 0.260 |
Why?
|
| Gene Expression Regulation, Leukemic | 3 | 2024 | 657 | 0.250 |
Why?
|
| Bone Marrow | 11 | 2025 | 2916 | 0.250 |
Why?
|
| Prospective Studies | 31 | 2022 | 54807 | 0.250 |
Why?
|
| Mediastinal Neoplasms | 2 | 2019 | 403 | 0.250 |
Why?
|
| Melphalan | 7 | 2019 | 425 | 0.250 |
Why?
|
| Lymphoma, B-Cell | 5 | 2019 | 943 | 0.250 |
Why?
|
| Lymphoma, Follicular | 6 | 2011 | 459 | 0.250 |
Why?
|
| Double-Blind Method | 6 | 2021 | 12417 | 0.250 |
Why?
|
| Minor Histocompatibility Antigens | 5 | 2011 | 303 | 0.250 |
Why?
|
| Antineoplastic Agents, Alkylating | 4 | 2018 | 614 | 0.250 |
Why?
|
| Lipoprotein-X | 1 | 2005 | 5 | 0.240 |
Why?
|
| Melanoma | 12 | 2010 | 5695 | 0.240 |
Why?
|
| Hematology | 1 | 2009 | 243 | 0.240 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2017 | 2769 | 0.240 |
Why?
|
| Adoptive Transfer | 3 | 2016 | 827 | 0.240 |
Why?
|
| Age Factors | 14 | 2024 | 18382 | 0.240 |
Why?
|
| Receptors, Interleukin-2 | 6 | 2006 | 561 | 0.240 |
Why?
|
| Azacitidine | 2 | 2024 | 334 | 0.230 |
Why?
|
| Dioxygenases | 3 | 2021 | 354 | 0.230 |
Why?
|
| Acute Kidney Injury | 4 | 2023 | 1943 | 0.220 |
Why?
|
| Research Personnel | 1 | 2009 | 589 | 0.220 |
Why?
|
| Graft Rejection | 5 | 2024 | 4503 | 0.220 |
Why?
|
| Drug Resistance | 4 | 2019 | 1588 | 0.220 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 4 | 2019 | 975 | 0.220 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 6 | 2013 | 696 | 0.210 |
Why?
|
| Mouth Mucosa | 3 | 2014 | 432 | 0.210 |
Why?
|
| Activated-Leukocyte Cell Adhesion Molecule | 1 | 2022 | 21 | 0.210 |
Why?
|
| Clinical Trials as Topic | 7 | 2012 | 8037 | 0.200 |
Why?
|
| Diet | 1 | 2021 | 8087 | 0.200 |
Why?
|
| Immunophenotyping | 11 | 2016 | 1865 | 0.200 |
Why?
|
| Hodgkin Disease | 4 | 2017 | 1383 | 0.200 |
Why?
|
| Stomatitis | 3 | 2016 | 270 | 0.200 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2023 | 1433 | 0.200 |
Why?
|
| Career Choice | 1 | 2009 | 769 | 0.200 |
Why?
|
| Cohort Studies | 26 | 2018 | 41680 | 0.200 |
Why?
|
| Receptors, Complement 3b | 2 | 2021 | 124 | 0.200 |
Why?
|
| Severity of Illness Index | 9 | 2020 | 15878 | 0.200 |
Why?
|
| Vaccination | 4 | 2023 | 3430 | 0.200 |
Why?
|
| Neoplasm, Residual | 5 | 2024 | 1009 | 0.200 |
Why?
|
| Leukemia, Experimental | 2 | 2020 | 224 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 12 | 2023 | 9373 | 0.200 |
Why?
|
| Cell Separation | 5 | 2016 | 1718 | 0.190 |
Why?
|
| Genomics | 1 | 2018 | 5925 | 0.190 |
Why?
|
| Recombinant Proteins | 14 | 2013 | 6491 | 0.190 |
Why?
|
| HLA-C Antigens | 2 | 2016 | 146 | 0.190 |
Why?
|
| Clone Cells | 7 | 2017 | 1670 | 0.190 |
Why?
|
| Isoantibodies | 5 | 2011 | 681 | 0.190 |
Why?
|
| Cytarabine | 5 | 2008 | 696 | 0.190 |
Why?
|
| BK Virus | 2 | 2020 | 120 | 0.190 |
Why?
|
| Forkhead Transcription Factors | 6 | 2018 | 1623 | 0.190 |
Why?
|
| Treatment Failure | 3 | 2024 | 2653 | 0.180 |
Why?
|
| Hematopoiesis | 8 | 2020 | 2060 | 0.180 |
Why?
|
| Teaching | 1 | 2009 | 1170 | 0.180 |
Why?
|
| Neoplasm Proteins | 6 | 2021 | 3592 | 0.180 |
Why?
|
| Fusion Proteins, bcr-abl | 5 | 2004 | 429 | 0.180 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 4 | 2016 | 305 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2021 | 6503 | 0.180 |
Why?
|
| Tandem Repeat Sequences | 2 | 2024 | 184 | 0.180 |
Why?
|
| Boronic Acids | 3 | 2014 | 915 | 0.180 |
Why?
|
| Antibodies, Viral | 4 | 2023 | 3213 | 0.170 |
Why?
|
| Glucans | 1 | 2020 | 71 | 0.170 |
Why?
|
| Lymphocyte Subsets | 3 | 2001 | 313 | 0.170 |
Why?
|
| Limbic Encephalitis | 2 | 2012 | 36 | 0.170 |
Why?
|
| Proteins | 4 | 2022 | 5994 | 0.160 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2023 | 273 | 0.160 |
Why?
|
| Prednisone | 11 | 2018 | 1566 | 0.160 |
Why?
|
| Antigens, Neoplasm | 6 | 2010 | 1995 | 0.160 |
Why?
|
| Herpesvirus 6, Human | 2 | 2012 | 97 | 0.160 |
Why?
|
| Viremia | 2 | 2014 | 727 | 0.160 |
Why?
|
| DNA, Mitochondrial | 1 | 2024 | 869 | 0.160 |
Why?
|
| Transplantation, Isogeneic | 3 | 2012 | 250 | 0.160 |
Why?
|
| beta-Glucans | 1 | 2020 | 129 | 0.160 |
Why?
|
| Gene Deletion | 3 | 2019 | 2667 | 0.160 |
Why?
|
| Child, Preschool | 15 | 2021 | 42510 | 0.160 |
Why?
|
| Neoplasms | 17 | 2022 | 22340 | 0.160 |
Why?
|
| Receptors, CXCR5 | 2 | 2016 | 88 | 0.160 |
Why?
|
| Idiopathic Interstitial Pneumonias | 2 | 2021 | 24 | 0.160 |
Why?
|
| Recovery of Function | 3 | 2019 | 2963 | 0.160 |
Why?
|
| Photopheresis | 1 | 2019 | 35 | 0.160 |
Why?
|
| Child | 22 | 2023 | 80568 | 0.160 |
Why?
|
| Blood Donors | 5 | 2013 | 344 | 0.160 |
Why?
|
| Patient Selection | 4 | 2020 | 4248 | 0.160 |
Why?
|
| Long QT Syndrome | 1 | 2023 | 474 | 0.150 |
Why?
|
| Risk Factors | 28 | 2021 | 74850 | 0.150 |
Why?
|
| Ferritins | 4 | 2012 | 600 | 0.150 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2022 | 797 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2018 | 190 | 0.150 |
Why?
|
| Aminoglycosides | 2 | 2012 | 161 | 0.150 |
Why?
|
| Flow Cytometry | 11 | 2015 | 5880 | 0.150 |
Why?
|
| Costs and Cost Analysis | 4 | 2016 | 1666 | 0.140 |
Why?
|
| Glucocorticoids | 3 | 2018 | 2155 | 0.140 |
Why?
|
| Lymphoproliferative Disorders | 3 | 2011 | 526 | 0.140 |
Why?
|
| Skin Diseases | 4 | 2020 | 1083 | 0.140 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2020 | 433 | 0.140 |
Why?
|
| Blood Component Removal | 2 | 2011 | 124 | 0.140 |
Why?
|
| Disease Management | 3 | 2020 | 2530 | 0.140 |
Why?
|
| Life Tables | 8 | 2003 | 366 | 0.140 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2023 | 615 | 0.140 |
Why?
|
| Dendritic Cells | 6 | 2023 | 2745 | 0.140 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2018 | 168 | 0.140 |
Why?
|
| HLA-DR7 Antigen | 1 | 1996 | 27 | 0.140 |
Why?
|
| Sulfonamides | 2 | 2024 | 1979 | 0.140 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 2002 | 1346 | 0.140 |
Why?
|
| Medical Oncology | 1 | 2009 | 2339 | 0.140 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2017 | 30 | 0.140 |
Why?
|
| Levonorgestrel | 1 | 2017 | 76 | 0.130 |
Why?
|
| Atovaquone | 1 | 2016 | 56 | 0.130 |
Why?
|
| Vasculitis | 1 | 2021 | 528 | 0.130 |
Why?
|
| Leukocyte Count | 4 | 2014 | 1605 | 0.130 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 2016 | 10 | 0.130 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 3249 | 0.130 |
Why?
|
| Intestinal Diseases | 2 | 2012 | 506 | 0.130 |
Why?
|
| Mycoses | 3 | 2011 | 389 | 0.130 |
Why?
|
| Liver Diseases | 1 | 2005 | 1304 | 0.130 |
Why?
|
| Hand Strength | 1 | 2019 | 462 | 0.130 |
Why?
|
| Mouth | 2 | 2009 | 382 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2016 | 10727 | 0.130 |
Why?
|
| Gangliosides | 1 | 1996 | 132 | 0.130 |
Why?
|
| Cell Count | 3 | 2016 | 1823 | 0.130 |
Why?
|
| Arabinonucleosides | 1 | 2015 | 35 | 0.120 |
Why?
|
| Risk | 11 | 2011 | 9599 | 0.120 |
Why?
|
| Endothelial Cells | 3 | 2021 | 3586 | 0.120 |
Why?
|
| Multivariate Analysis | 10 | 2016 | 12059 | 0.120 |
Why?
|
| Adenine Nucleotides | 1 | 2015 | 111 | 0.120 |
Why?
|
| ABO Blood-Group System | 2 | 1997 | 381 | 0.120 |
Why?
|
| Blood Specimen Collection | 1 | 2016 | 238 | 0.120 |
Why?
|
| Aged, 80 and over | 17 | 2022 | 59496 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 3 | 2017 | 1056 | 0.120 |
Why?
|
| Tissue Banks | 1 | 2016 | 183 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2018 | 3733 | 0.120 |
Why?
|
| Food Supply | 1 | 2021 | 544 | 0.120 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 2 | 2018 | 94 | 0.120 |
Why?
|
| Animals | 28 | 2024 | 168735 | 0.120 |
Why?
|
| Piperidines | 2 | 2021 | 1664 | 0.120 |
Why?
|
| Lung Diseases | 3 | 2019 | 1939 | 0.120 |
Why?
|
| Cytokines | 7 | 2021 | 7417 | 0.120 |
Why?
|
| H-Y Antigen | 2 | 2004 | 42 | 0.120 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 904 | 0.120 |
Why?
|
| Rhizomucor | 1 | 2014 | 3 | 0.110 |
Why?
|
| Interleukins | 3 | 2014 | 789 | 0.110 |
Why?
|
| Endothelium, Vascular | 2 | 2021 | 4423 | 0.110 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2019 | 504 | 0.110 |
Why?
|
| Liver | 5 | 2012 | 7559 | 0.110 |
Why?
|
| Antibody Formation | 6 | 2017 | 1392 | 0.110 |
Why?
|
| Drug Therapy, Combination | 8 | 2021 | 6306 | 0.110 |
Why?
|
| Disease Progression | 12 | 2019 | 13614 | 0.110 |
Why?
|
| Immunoconjugates | 2 | 2017 | 976 | 0.110 |
Why?
|
| Colitis | 2 | 2013 | 1239 | 0.110 |
Why?
|
| 16,16-Dimethylprostaglandin E2 | 1 | 2013 | 22 | 0.110 |
Why?
|
| Bradyrhizobium | 1 | 2013 | 16 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 2 | 2010 | 1351 | 0.110 |
Why?
|
| Gait | 1 | 2019 | 819 | 0.110 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2013 | 1104 | 0.110 |
Why?
|
| Transplantation Immunology | 4 | 2016 | 540 | 0.110 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2013 | 49 | 0.110 |
Why?
|
| Risk Assessment | 8 | 2019 | 24275 | 0.100 |
Why?
|
| Drug Administration Schedule | 3 | 2017 | 4851 | 0.100 |
Why?
|
| Validation Studies as Topic | 2 | 2012 | 162 | 0.100 |
Why?
|
| Small Molecule Libraries | 1 | 2018 | 740 | 0.100 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2014 | 254 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2024 | 3604 | 0.100 |
Why?
|
| Patient Readmission | 3 | 2016 | 3282 | 0.100 |
Why?
|
| Syndrome | 4 | 2018 | 3271 | 0.100 |
Why?
|
| Immune Tolerance | 3 | 2019 | 2324 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2023 | 4044 | 0.100 |
Why?
|
| DNA-Binding Proteins | 5 | 2021 | 9600 | 0.100 |
Why?
|
| Mucormycosis | 1 | 2014 | 104 | 0.100 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 1992 | 58 | 0.100 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 1084 | 0.100 |
Why?
|
| Receptors, KIR | 1 | 2013 | 114 | 0.100 |
Why?
|
| Integrin alpha4 | 1 | 2012 | 89 | 0.100 |
Why?
|
| Antimicrobial Cationic Peptides | 2 | 2011 | 348 | 0.100 |
Why?
|
| Administration, Topical | 4 | 2020 | 702 | 0.100 |
Why?
|
| Heterocyclic Compounds | 1 | 2013 | 245 | 0.100 |
Why?
|
| Vaccines, Attenuated | 1 | 2013 | 313 | 0.100 |
Why?
|
| Integrin beta Chains | 1 | 2012 | 116 | 0.100 |
Why?
|
| Infant | 8 | 2021 | 36426 | 0.100 |
Why?
|
| Mice | 20 | 2024 | 81782 | 0.100 |
Why?
|
| Immunocompromised Host | 3 | 2014 | 865 | 0.100 |
Why?
|
| Gene Frequency | 2 | 2018 | 3623 | 0.100 |
Why?
|
| STAT3 Transcription Factor | 1 | 2016 | 871 | 0.100 |
Why?
|
| DEAD-box RNA Helicases | 3 | 2011 | 386 | 0.100 |
Why?
|
| Chelation Therapy | 1 | 2012 | 76 | 0.100 |
Why?
|
| DNA, Neoplasm | 2 | 2016 | 1739 | 0.100 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2012 | 73 | 0.100 |
Why?
|
| Immunity, Humoral | 3 | 2010 | 607 | 0.100 |
Why?
|
| Respiration, Artificial | 2 | 2020 | 2726 | 0.100 |
Why?
|
| Roseolovirus Infections | 1 | 2012 | 49 | 0.100 |
Why?
|
| Skin Neoplasms | 4 | 2023 | 5836 | 0.100 |
Why?
|
| Polyomavirus Infections | 1 | 2014 | 193 | 0.100 |
Why?
|
| Oral Health | 1 | 2017 | 493 | 0.100 |
Why?
|
| Topography, Medical | 1 | 2011 | 37 | 0.100 |
Why?
|
| Tumor Microenvironment | 1 | 2025 | 3940 | 0.090 |
Why?
|
| Homeostasis | 3 | 2013 | 3338 | 0.090 |
Why?
|
| Gene Library | 6 | 2014 | 1066 | 0.090 |
Why?
|
| Ovarian Neoplasms | 3 | 2024 | 4904 | 0.090 |
Why?
|
| Benzamides | 4 | 2005 | 1376 | 0.090 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2014 | 588 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 3661 | 0.090 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2022 | 2674 | 0.090 |
Why?
|
| Iron Chelating Agents | 1 | 2012 | 141 | 0.090 |
Why?
|
| Gene Expression | 6 | 2016 | 7581 | 0.090 |
Why?
|
| Vascular Diseases | 1 | 2019 | 1161 | 0.090 |
Why?
|
| Burkitt Lymphoma | 1 | 1993 | 338 | 0.090 |
Why?
|
| Tumor Virus Infections | 1 | 2014 | 438 | 0.090 |
Why?
|
| Integrins | 3 | 2009 | 838 | 0.090 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 2036 | 0.090 |
Why?
|
| Physician Assistants | 1 | 2013 | 190 | 0.090 |
Why?
|
| Immunotherapy, Active | 1 | 2010 | 58 | 0.090 |
Why?
|
| Infusions, Intravenous | 5 | 2012 | 2227 | 0.090 |
Why?
|
| STAT5 Transcription Factor | 3 | 2017 | 268 | 0.090 |
Why?
|
| Oral Ulcer | 2 | 2009 | 95 | 0.090 |
Why?
|
| Academic Medical Centers | 2 | 2013 | 2782 | 0.090 |
Why?
|
| Receptors, Antigen, T-Cell | 7 | 2019 | 2570 | 0.090 |
Why?
|
| Neprilysin | 1 | 1993 | 484 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 5 | 2020 | 6209 | 0.090 |
Why?
|
| Renal Dialysis | 1 | 2020 | 1791 | 0.090 |
Why?
|
| Blood Coagulation Factors | 1 | 2012 | 372 | 0.090 |
Why?
|
| Sezary Syndrome | 1 | 2011 | 70 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2020 | 1729 | 0.090 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2010 | 110 | 0.090 |
Why?
|
| Bacteremia | 1 | 2017 | 988 | 0.090 |
Why?
|
| Immunity, Innate | 3 | 2011 | 3078 | 0.090 |
Why?
|
| Hypersensitivity, Delayed | 2 | 2003 | 490 | 0.090 |
Why?
|
| Pneumococcal Vaccines | 2 | 2005 | 413 | 0.080 |
Why?
|
| Observation | 1 | 2011 | 309 | 0.080 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2019 | 1076 | 0.080 |
Why?
|
| Radiation Injuries | 2 | 2011 | 1181 | 0.080 |
Why?
|
| HLA-A2 Antigen | 3 | 2022 | 207 | 0.080 |
Why?
|
| Rectum | 1 | 2014 | 895 | 0.080 |
Why?
|
| Fluoroquinolones | 1 | 2011 | 307 | 0.080 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2010 | 246 | 0.080 |
Why?
|
| Mice, Knockout | 6 | 2024 | 14450 | 0.080 |
Why?
|
| Proportional Hazards Models | 7 | 2020 | 12529 | 0.080 |
Why?
|
| Adjuvants, Immunologic | 1 | 1995 | 993 | 0.080 |
Why?
|
| Hemolytic-Uremic Syndrome | 2 | 2005 | 105 | 0.080 |
Why?
|
| Pyrazoles | 2 | 2023 | 2031 | 0.080 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2010 | 825 | 0.080 |
Why?
|
| Mycosis Fungoides | 1 | 2011 | 154 | 0.080 |
Why?
|
| Oral Medicine | 1 | 2009 | 36 | 0.080 |
Why?
|
| Nuclear Proteins | 3 | 2018 | 5782 | 0.080 |
Why?
|
| Immunomagnetic Separation | 2 | 2011 | 78 | 0.080 |
Why?
|
| Boston | 6 | 2019 | 9334 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2020 | 4520 | 0.080 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2011 | 125 | 0.080 |
Why?
|
| Stress, Psychological | 1 | 2005 | 4527 | 0.080 |
Why?
|
| Lymphoid Tissue | 1 | 1991 | 444 | 0.080 |
Why?
|
| Antigen-Antibody Complex | 1 | 2011 | 508 | 0.080 |
Why?
|
| Transplantation | 1 | 2011 | 222 | 0.080 |
Why?
|
| Job Application | 1 | 2009 | 38 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 2004 | 0.080 |
Why?
|
| Length of Stay | 7 | 2015 | 6486 | 0.080 |
Why?
|
| Neoplasm Metastasis | 5 | 2003 | 4882 | 0.080 |
Why?
|
| Chromosomes, Human, Y | 1 | 2010 | 163 | 0.080 |
Why?
|
| Peptide Fragments | 3 | 2014 | 5126 | 0.080 |
Why?
|
| Skin | 2 | 2020 | 4481 | 0.080 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2019 | 1663 | 0.080 |
Why?
|
| Health Status Indicators | 1 | 2014 | 967 | 0.080 |
Why?
|
| K562 Cells | 4 | 2013 | 644 | 0.080 |
Why?
|
| Bronchi | 1 | 2012 | 843 | 0.080 |
Why?
|
| Antifungal Agents | 1 | 2014 | 769 | 0.080 |
Why?
|
| Nitriles | 1 | 2014 | 981 | 0.080 |
Why?
|
| Maximum Tolerated Dose | 3 | 2019 | 895 | 0.080 |
Why?
|
| Drug Discovery | 1 | 2016 | 1062 | 0.080 |
Why?
|
| Cryopreservation | 3 | 2021 | 727 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2016 | 8603 | 0.080 |
Why?
|
| Triazoles | 1 | 2014 | 898 | 0.080 |
Why?
|
| Premedication | 2 | 2008 | 245 | 0.080 |
Why?
|
| Radiography, Thoracic | 1 | 2015 | 1319 | 0.070 |
Why?
|
| Financial Support | 1 | 2009 | 116 | 0.070 |
Why?
|
| Spinal Nerves | 1 | 2008 | 93 | 0.070 |
Why?
|
| Socioeconomic Factors | 3 | 2018 | 7842 | 0.070 |
Why?
|
| Interferon-gamma | 6 | 2020 | 3158 | 0.070 |
Why?
|
| Salvage Therapy | 4 | 2006 | 1272 | 0.070 |
Why?
|
| Secondary Prevention | 3 | 2005 | 1470 | 0.070 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2009 | 240 | 0.070 |
Why?
|
| Pilot Projects | 6 | 2012 | 8724 | 0.070 |
Why?
|
| Toll-Like Receptors | 1 | 2011 | 582 | 0.070 |
Why?
|
| Income | 1 | 2016 | 1874 | 0.070 |
Why?
|
| Bone Marrow Cells | 6 | 2013 | 2411 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 7473 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2025 | 1800 | 0.070 |
Why?
|
| Financing, Organized | 1 | 2009 | 202 | 0.070 |
Why?
|
| Thymus Gland | 2 | 2010 | 1259 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 8 | 2020 | 22327 | 0.070 |
Why?
|
| Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2006 | 11 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2015 | 2423 | 0.070 |
Why?
|
| Cell Nucleus | 1 | 2016 | 2864 | 0.070 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2007 | 65 | 0.070 |
Why?
|
| Protein Disulfide-Isomerases | 1 | 2008 | 209 | 0.070 |
Why?
|
| Genetic Engineering | 3 | 2003 | 933 | 0.070 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2010 | 452 | 0.070 |
Why?
|
| Bilirubin | 3 | 2023 | 439 | 0.070 |
Why?
|
| Breast Neoplasms | 3 | 2010 | 21069 | 0.070 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2008 | 249 | 0.070 |
Why?
|
| Career Mobility | 1 | 2009 | 261 | 0.070 |
Why?
|
| Epithelium | 1 | 2011 | 1603 | 0.070 |
Why?
|
| Antibody Specificity | 4 | 2011 | 1061 | 0.070 |
Why?
|
| Telomerase | 1 | 2011 | 749 | 0.070 |
Why?
|
| Blood Proteins | 1 | 2011 | 1186 | 0.070 |
Why?
|
| Venous Thromboembolism | 2 | 2017 | 1883 | 0.070 |
Why?
|
| HIV-1 | 2 | 2014 | 6945 | 0.060 |
Why?
|
| Infant, Newborn | 5 | 2020 | 26380 | 0.060 |
Why?
|
| Karyotyping | 4 | 2012 | 1175 | 0.060 |
Why?
|
| Mycophenolic Acid | 3 | 2014 | 348 | 0.060 |
Why?
|
| Virus Activation | 2 | 2012 | 322 | 0.060 |
Why?
|
| Anemia, Aplastic | 1 | 2008 | 231 | 0.060 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2009 | 1362 | 0.060 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2006 | 108 | 0.060 |
Why?
|
| Leukocytes | 1 | 2014 | 2027 | 0.060 |
Why?
|
| Isocitrate Dehydrogenase | 2 | 2023 | 954 | 0.060 |
Why?
|
| Chromosome Aberrations | 2 | 2009 | 1775 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2010 | 3801 | 0.060 |
Why?
|
| Parathyroid Hormone | 1 | 2012 | 1790 | 0.060 |
Why?
|
| Interferon-alpha | 4 | 2011 | 909 | 0.060 |
Why?
|
| Iron | 2 | 2012 | 1811 | 0.060 |
Why?
|
| STAT Transcription Factors | 1 | 2006 | 189 | 0.060 |
Why?
|
| Pyridines | 2 | 2015 | 2885 | 0.060 |
Why?
|
| Colon | 1 | 2013 | 1796 | 0.060 |
Why?
|
| Stress, Physiological | 1 | 2012 | 1404 | 0.060 |
Why?
|
| Health Expenditures | 1 | 2018 | 2388 | 0.060 |
Why?
|
| Blood Platelets | 2 | 2013 | 2464 | 0.060 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 3230 | 0.060 |
Why?
|
| Necrosis | 3 | 2003 | 1611 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 2879 | 0.060 |
Why?
|
| Longitudinal Studies | 5 | 2021 | 14745 | 0.060 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2005 | 112 | 0.060 |
Why?
|
| Living Donors | 1 | 2009 | 647 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2005 | 4563 | 0.060 |
Why?
|
| Protein Array Analysis | 3 | 2012 | 398 | 0.060 |
Why?
|
| Ligands | 2 | 2024 | 3272 | 0.060 |
Why?
|
| Postoperative Complications | 3 | 2014 | 15802 | 0.060 |
Why?
|
| Thrombocytopenia | 2 | 2008 | 1172 | 0.060 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2007 | 869 | 0.060 |
Why?
|
| Sick Role | 1 | 2005 | 229 | 0.060 |
Why?
|
| Melanoma, Experimental | 2 | 2010 | 555 | 0.060 |
Why?
|
| Leukopenia | 2 | 2017 | 213 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 9 | 2013 | 6058 | 0.060 |
Why?
|
| Pandemics | 2 | 2021 | 8721 | 0.060 |
Why?
|
| Health Status | 2 | 2016 | 4085 | 0.060 |
Why?
|
| Case-Control Studies | 9 | 2014 | 22228 | 0.060 |
Why?
|
| Decision Making | 2 | 2016 | 3955 | 0.060 |
Why?
|
| Mice, Inbred NOD | 2 | 2020 | 1837 | 0.060 |
Why?
|
| Paraproteinemias | 1 | 2006 | 251 | 0.060 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2005 | 102 | 0.060 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2005 | 132 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 5 | 2017 | 4780 | 0.050 |
Why?
|
| Viral Load | 1 | 2013 | 3385 | 0.050 |
Why?
|
| Feasibility Studies | 4 | 2012 | 5300 | 0.050 |
Why?
|
| Goals | 1 | 2009 | 717 | 0.050 |
Why?
|
| Universities | 1 | 2009 | 1004 | 0.050 |
Why?
|
| Vulvar Diseases | 1 | 2003 | 64 | 0.050 |
Why?
|
| Diphtheria Toxin | 1 | 2004 | 253 | 0.050 |
Why?
|
| Mentors | 1 | 2009 | 671 | 0.050 |
Why?
|
| Influenza Vaccines | 1 | 2010 | 780 | 0.050 |
Why?
|
| Repetitive Sequences, Amino Acid | 1 | 2003 | 91 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2021 | 2838 | 0.050 |
Why?
|
| Monitoring, Physiologic | 2 | 2008 | 1793 | 0.050 |
Why?
|
| Vaginal Diseases | 1 | 2003 | 103 | 0.050 |
Why?
|
| Gene Duplication | 1 | 2024 | 316 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2020 | 2626 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2012 | 2248 | 0.050 |
Why?
|
| Cause of Death | 2 | 2004 | 3715 | 0.050 |
Why?
|
| Receptors, Opioid | 1 | 2003 | 144 | 0.050 |
Why?
|
| Kidney | 1 | 2018 | 7073 | 0.050 |
Why?
|
| GPI-Linked Proteins | 1 | 2024 | 472 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2017 | 1407 | 0.050 |
Why?
|
| Alleles | 3 | 2021 | 6891 | 0.050 |
Why?
|
| Adenine | 2 | 2021 | 994 | 0.050 |
Why?
|
| Antibodies, Blocking | 1 | 2003 | 249 | 0.050 |
Why?
|
| Fetal Proteins | 1 | 2022 | 99 | 0.050 |
Why?
|
| Drug Monitoring | 2 | 2012 | 960 | 0.050 |
Why?
|
| Immunoglobulin M | 2 | 2019 | 1527 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2008 | 2075 | 0.050 |
Why?
|
| Cell Proliferation | 4 | 2019 | 10426 | 0.050 |
Why?
|
| Polycythemia Vera | 1 | 2003 | 160 | 0.050 |
Why?
|
| Interleukin-11 | 1 | 2002 | 58 | 0.050 |
Why?
|
| Immunization | 2 | 2005 | 1218 | 0.050 |
Why?
|
| Drug Compounding | 2 | 2018 | 236 | 0.050 |
Why?
|
| Genetic Variation | 3 | 2019 | 6612 | 0.050 |
Why?
|
| Cells, Cultured | 6 | 2016 | 18962 | 0.050 |
Why?
|
| Leukopoiesis | 1 | 2001 | 54 | 0.050 |
Why?
|
| Cholestasis | 1 | 2005 | 385 | 0.050 |
Why?
|
| Acetamides | 1 | 2023 | 260 | 0.050 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2001 | 111 | 0.050 |
Why?
|
| Publishing | 1 | 2009 | 836 | 0.050 |
Why?
|
| Data Collection | 5 | 2011 | 3318 | 0.050 |
Why?
|
| Sialoglycoproteins | 1 | 2002 | 313 | 0.050 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2002 | 260 | 0.050 |
Why?
|
| Renal Replacement Therapy | 1 | 2023 | 283 | 0.050 |
Why?
|
| Disease Models, Animal | 5 | 2020 | 18292 | 0.050 |
Why?
|
| Fatigue | 1 | 2008 | 1553 | 0.050 |
Why?
|
| Aging | 2 | 2010 | 8725 | 0.050 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2022 | 262 | 0.050 |
Why?
|
| Genotype | 4 | 2024 | 13026 | 0.050 |
Why?
|
| Mitochondria | 1 | 2014 | 3669 | 0.040 |
Why?
|
| Fatal Outcome | 2 | 2003 | 1835 | 0.040 |
Why?
|
| Forehead | 1 | 2021 | 75 | 0.040 |
Why?
|
| Mitochondrial Proteins | 1 | 2006 | 975 | 0.040 |
Why?
|
| Odds Ratio | 3 | 2020 | 9656 | 0.040 |
Why?
|
| Gene Expression Profiling | 4 | 2024 | 9525 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2016 | 10380 | 0.040 |
Why?
|
| Statistics, Nonparametric | 3 | 2017 | 2844 | 0.040 |
Why?
|
| Vacuolar Proton-Translocating ATPases | 1 | 2002 | 196 | 0.040 |
Why?
|
| Viral Tropism | 1 | 2021 | 101 | 0.040 |
Why?
|
| Vital Capacity | 2 | 2014 | 995 | 0.040 |
Why?
|
| Apoptosis | 4 | 2021 | 9505 | 0.040 |
Why?
|
| Antigen-Presenting Cells | 2 | 2020 | 960 | 0.040 |
Why?
|
| Ohio | 1 | 2021 | 320 | 0.040 |
Why?
|
| Diterpenes | 1 | 2021 | 166 | 0.040 |
Why?
|
| Antigens, Differentiation | 1 | 2003 | 919 | 0.040 |
Why?
|
| Receptor-CD3 Complex, Antigen, T-Cell | 1 | 2000 | 67 | 0.040 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2000 | 70 | 0.040 |
Why?
|
| Hemorrhage | 3 | 2020 | 3466 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 622 | 0.040 |
Why?
|
| Polypharmacy | 1 | 2022 | 306 | 0.040 |
Why?
|
| Antigens, CD19 | 1 | 2023 | 442 | 0.040 |
Why?
|
| Immune System | 2 | 2002 | 799 | 0.040 |
Why?
|
| Phenotype | 6 | 2024 | 16714 | 0.040 |
Why?
|
| Acetates | 1 | 2021 | 314 | 0.040 |
Why?
|
| Life Change Events | 1 | 2005 | 956 | 0.040 |
Why?
|
| Glucuronidase | 1 | 2021 | 205 | 0.040 |
Why?
|
| Complementarity Determining Regions | 1 | 2000 | 154 | 0.040 |
Why?
|
| Germany | 1 | 2021 | 882 | 0.040 |
Why?
|
| Organ Specificity | 2 | 2021 | 1964 | 0.040 |
Why?
|
| Influenza, Human | 1 | 2010 | 1539 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2003 | 1092 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 4249 | 0.040 |
Why?
|
| Vincristine | 6 | 1998 | 1037 | 0.040 |
Why?
|
| Dermatologic Agents | 1 | 2003 | 314 | 0.040 |
Why?
|
| Cell Line, Tumor | 4 | 2024 | 17060 | 0.040 |
Why?
|
| Propylene Glycol | 1 | 2018 | 29 | 0.040 |
Why?
|
| Vitamin D | 1 | 2012 | 3272 | 0.040 |
Why?
|
| Crohn Disease | 1 | 2011 | 2281 | 0.040 |
Why?
|
| Phosphotyrosine | 2 | 2016 | 459 | 0.040 |
Why?
|
| Phosphorylation | 4 | 2017 | 8279 | 0.040 |
Why?
|
| Receptors, Very Late Antigen | 2 | 1997 | 74 | 0.040 |
Why?
|
| Growth Substances | 1 | 2001 | 758 | 0.040 |
Why?
|
| Models, Biological | 1 | 2015 | 9443 | 0.040 |
Why?
|
| Gene Expression Regulation | 3 | 2012 | 11895 | 0.040 |
Why?
|
| Oncogenes | 1 | 2024 | 1232 | 0.040 |
Why?
|
| Enzyme Inhibitors | 2 | 2022 | 3716 | 0.040 |
Why?
|
| Scleroderma, Localized | 1 | 2019 | 84 | 0.040 |
Why?
|
| beta 2-Microglobulin | 1 | 2019 | 330 | 0.040 |
Why?
|
| Forced Expiratory Volume | 2 | 2014 | 1828 | 0.040 |
Why?
|
| Inflammation Mediators | 2 | 2011 | 1886 | 0.040 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2020 | 216 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2020 | 2945 | 0.040 |
Why?
|
| Thrombophilia | 1 | 2021 | 308 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2023 | 1077 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2001 | 451 | 0.040 |
Why?
|
| Wounds and Injuries | 1 | 2011 | 2513 | 0.040 |
Why?
|
| Polyradiculoneuropathy | 1 | 1997 | 65 | 0.040 |
Why?
|
| Molecular Sequence Data | 8 | 2004 | 17596 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2012 | 5088 | 0.040 |
Why?
|
| Eosinophils | 2 | 2002 | 946 | 0.040 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 1997 | 141 | 0.040 |
Why?
|
| HLA-A Antigens | 2 | 2010 | 223 | 0.040 |
Why?
|
| Hemagglutinins | 1 | 1997 | 111 | 0.040 |
Why?
|
| Gravidity | 1 | 2017 | 50 | 0.040 |
Why?
|
| Ambulatory Care | 2 | 2007 | 2778 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 637 | 0.040 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 2 | 2002 | 304 | 0.030 |
Why?
|
| HIV Infections | 2 | 2014 | 17531 | 0.030 |
Why?
|
| Massachusetts | 2 | 2021 | 8882 | 0.030 |
Why?
|
| United States | 8 | 2021 | 72909 | 0.030 |
Why?
|
| Blood Group Incompatibility | 1 | 1997 | 134 | 0.030 |
Why?
|
| Blood Component Transfusion | 1 | 1997 | 141 | 0.030 |
Why?
|
| Down-Regulation | 2 | 2016 | 2925 | 0.030 |
Why?
|
| Lymphatic Irradiation | 1 | 1997 | 110 | 0.030 |
Why?
|
| Respiration Disorders | 1 | 2020 | 364 | 0.030 |
Why?
|
| Cytokine Receptor gp130 | 1 | 2016 | 66 | 0.030 |
Why?
|
| Progesterone | 1 | 2021 | 751 | 0.030 |
Why?
|
| Antigens, CD20 | 2 | 2014 | 198 | 0.030 |
Why?
|
| Lymphocyte Cooperation | 1 | 2016 | 112 | 0.030 |
Why?
|
| Heparin | 2 | 2021 | 1632 | 0.030 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 11196 | 0.030 |
Why?
|
| Comorbidity | 3 | 2018 | 10575 | 0.030 |
Why?
|
| Reoperation | 1 | 2006 | 4308 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2001 | 1692 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2019 | 586 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2019 | 1748 | 0.030 |
Why?
|
| Contraceptive Agents, Female | 1 | 2017 | 122 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 878 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 1998 | 667 | 0.030 |
Why?
|
| Cholesterol | 1 | 2005 | 2902 | 0.030 |
Why?
|
| Prevalence | 3 | 2018 | 15828 | 0.030 |
Why?
|
| Menstruation | 1 | 2017 | 310 | 0.030 |
Why?
|
| Translocation, Genetic | 2 | 2005 | 1393 | 0.030 |
Why?
|
| Lymphopoiesis | 1 | 2016 | 132 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2017 | 871 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2014 | 1899 | 0.030 |
Why?
|
| Donor Selection | 1 | 2017 | 242 | 0.030 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1996 | 489 | 0.030 |
Why?
|
| Doxorubicin | 6 | 1998 | 2226 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 1996 | 1079 | 0.030 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 1995 | 93 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 3690 | 0.030 |
Why?
|
| Plasma Cells | 2 | 2016 | 596 | 0.030 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2019 | 582 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 1995 | 191 | 0.030 |
Why?
|
| Quinazolines | 1 | 2021 | 1366 | 0.030 |
Why?
|
| Receptors, Interleukin-21 | 1 | 2014 | 32 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 2007 | 533 | 0.030 |
Why?
|
| Isoquinolines | 1 | 2016 | 350 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2020 | 833 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 1787 | 0.030 |
Why?
|
| Hepatitis B virus | 1 | 1998 | 532 | 0.030 |
Why?
|
| Attitude to Health | 1 | 2003 | 2020 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2020 | 2915 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2020 | 921 | 0.030 |
Why?
|
| Plasma | 1 | 1997 | 583 | 0.030 |
Why?
|
| Transplants | 1 | 2016 | 208 | 0.030 |
Why?
|
| Platelet Count | 1 | 2017 | 784 | 0.030 |
Why?
|
| Cell Lineage | 2 | 2016 | 2573 | 0.030 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 230 | 0.030 |
Why?
|
| Immunohistochemistry | 3 | 2018 | 11030 | 0.030 |
Why?
|
| Biopsy | 3 | 2013 | 6766 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2018 | 548 | 0.030 |
Why?
|
| Interleukin-12 | 2 | 1993 | 581 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2005 | 2662 | 0.030 |
Why?
|
| Immunization, Passive | 1 | 1996 | 616 | 0.030 |
Why?
|
| Exoribonucleases | 2 | 2005 | 88 | 0.030 |
Why?
|
| Vaccines | 1 | 2022 | 840 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 360 | 0.030 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 1994 | 99 | 0.030 |
Why?
|
| Frail Elderly | 1 | 2019 | 782 | 0.030 |
Why?
|
| Filgrastim | 1 | 2013 | 132 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2016 | 711 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2001 | 2760 | 0.030 |
Why?
|
| Morbidity | 1 | 2019 | 1752 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2008 | 3183 | 0.030 |
Why?
|
| Macrophages | 2 | 2018 | 5772 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2015 | 2470 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 4 | 2003 | 6101 | 0.030 |
Why?
|
| Activities of Daily Living | 2 | 2019 | 2414 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2016 | 853 | 0.030 |
Why?
|
| Antiviral Agents | 2 | 2021 | 3053 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1997 | 678 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 2536 | 0.030 |
Why?
|
| Bronchography | 1 | 2012 | 69 | 0.030 |
Why?
|
| Oxazines | 1 | 2015 | 358 | 0.030 |
Why?
|
| Emotions | 1 | 2005 | 2759 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 3 | 2002 | 812 | 0.030 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 1995 | 258 | 0.030 |
Why?
|
| Benzylamines | 1 | 2013 | 251 | 0.030 |
Why?
|
| Infusions, Subcutaneous | 1 | 2012 | 43 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2003 | 2897 | 0.030 |
Why?
|
| Receptors, HIV | 1 | 2013 | 159 | 0.030 |
Why?
|
| Gene Rearrangement | 2 | 2002 | 1143 | 0.030 |
Why?
|
| Hepatitis B | 1 | 1998 | 709 | 0.030 |
Why?
|
| Hospital Costs | 1 | 1998 | 955 | 0.020 |
Why?
|
| Anemia, Sickle Cell | 1 | 2021 | 1063 | 0.020 |
Why?
|
| Paraffin Embedding | 1 | 2013 | 302 | 0.020 |
Why?
|
| Neutrophils | 3 | 2016 | 3769 | 0.020 |
Why?
|
| CD40 Ligand | 1 | 2014 | 528 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 2008 | 0.020 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2012 | 70 | 0.020 |
Why?
|
| Vaccines, Conjugate | 2 | 2005 | 334 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 2001 | 1241 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 2 | 2008 | 7423 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2016 | 1336 | 0.020 |
Why?
|
| Intestinal Mucosa | 2 | 2014 | 3048 | 0.020 |
Why?
|
| Morpholines | 1 | 2015 | 577 | 0.020 |
Why?
|
| Death | 1 | 2016 | 686 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2008 | 4278 | 0.020 |
Why?
|
| Deferoxamine | 1 | 2012 | 154 | 0.020 |
Why?
|
| Airway Remodeling | 1 | 2012 | 134 | 0.020 |
Why?
|
| Random Allocation | 1 | 2016 | 2394 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2000 | 3542 | 0.020 |
Why?
|
| Memory, Short-Term | 1 | 2018 | 1002 | 0.020 |
Why?
|
| Antigen Presentation | 2 | 2010 | 1250 | 0.020 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 1996 | 365 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2019 | 16039 | 0.020 |
Why?
|
| Fusarium | 1 | 1991 | 50 | 0.020 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2011 | 340 | 0.020 |
Why?
|
| Chemokine CCL3 | 1 | 2011 | 84 | 0.020 |
Why?
|
| Host vs Graft Reaction | 1 | 1990 | 13 | 0.020 |
Why?
|
| Immunoglobulin A | 1 | 1995 | 992 | 0.020 |
Why?
|
| Aminopyridines | 1 | 2015 | 576 | 0.020 |
Why?
|
| Dilatation, Pathologic | 1 | 2012 | 527 | 0.020 |
Why?
|
| Up-Regulation | 2 | 2011 | 4130 | 0.020 |
Why?
|
| Blotting, Northern | 2 | 2003 | 1546 | 0.020 |
Why?
|
| Aftercare | 1 | 2017 | 915 | 0.020 |
Why?
|
| Haplotypes | 1 | 2017 | 2726 | 0.020 |
Why?
|
| Hypotension | 1 | 2017 | 885 | 0.020 |
Why?
|
| Anemia, Hemolytic | 1 | 1992 | 164 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2017 | 2603 | 0.020 |
Why?
|
| Cell Division | 2 | 2006 | 4466 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2021 | 3225 | 0.020 |
Why?
|
| Drug Evaluation | 2 | 2005 | 642 | 0.020 |
Why?
|
| Receptors, CCR5 | 1 | 2013 | 491 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2011 | 404 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 1992 | 280 | 0.020 |
Why?
|
| Critical Illness | 1 | 2023 | 2749 | 0.020 |
Why?
|
| Physicians | 1 | 2008 | 4591 | 0.020 |
Why?
|
| Phytohemagglutinins | 1 | 1990 | 164 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2014 | 1149 | 0.020 |
Why?
|
| Solubility | 1 | 2012 | 1077 | 0.020 |
Why?
|
| Eosinophilia | 1 | 1995 | 553 | 0.020 |
Why?
|
| Drug Costs | 1 | 1998 | 1194 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2017 | 2194 | 0.020 |
Why?
|
| Angiopoietin-1 | 1 | 2010 | 132 | 0.020 |
Why?
|
| Internet | 2 | 2016 | 3106 | 0.020 |
Why?
|
| Twins | 1 | 2012 | 340 | 0.020 |
Why?
|
| Endotoxemia | 1 | 2011 | 198 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2010 | 5019 | 0.020 |
Why?
|
| Receptor, TIE-2 | 1 | 2010 | 183 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 2586 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 1991 | 527 | 0.020 |
Why?
|
| Lichenoid Eruptions | 1 | 2009 | 13 | 0.020 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2010 | 71 | 0.020 |
Why?
|
| Pancytopenia | 1 | 1990 | 102 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2003 | 4909 | 0.020 |
Why?
|
| Chemokine CXCL10 | 1 | 2011 | 310 | 0.020 |
Why?
|
| Anxiety | 1 | 2005 | 4669 | 0.020 |
Why?
|
| DNA, Complementary | 2 | 2003 | 1984 | 0.020 |
Why?
|
| Angiopoietin-2 | 1 | 2010 | 186 | 0.020 |
Why?
|
| Thrombomodulin | 1 | 2010 | 107 | 0.020 |
Why?
|
| Th17 Cells | 1 | 2016 | 786 | 0.020 |
Why?
|
| Mucocele | 1 | 2009 | 51 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 1331 | 0.020 |
Why?
|
| Endotoxins | 1 | 2011 | 516 | 0.020 |
Why?
|
| Antibodies, Antinuclear | 1 | 2010 | 340 | 0.020 |
Why?
|
| Glucuronosyltransferase | 1 | 2009 | 136 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2022 | 3615 | 0.020 |
Why?
|
| Pneumococcal Infections | 2 | 2005 | 527 | 0.020 |
Why?
|
| Immunodominant Epitopes | 1 | 2010 | 244 | 0.020 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 2005 | 647 | 0.020 |
Why?
|
| Mass Screening | 1 | 2005 | 5449 | 0.020 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 26282 | 0.020 |
Why?
|
| Ablation Techniques | 1 | 2011 | 254 | 0.020 |
Why?
|
| Hepatorenal Syndrome | 1 | 2009 | 76 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2013 | 1476 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 1994 | 1555 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 4111 | 0.020 |
Why?
|
| Nucleic Acids | 1 | 2011 | 189 | 0.020 |
Why?
|
| Base Sequence | 4 | 2003 | 12405 | 0.020 |
Why?
|
| Genome, Bacterial | 1 | 2013 | 796 | 0.020 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2010 | 246 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 1966 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2010 | 1376 | 0.020 |
Why?
|
| Statistics as Topic | 2 | 2009 | 2350 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 15401 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2013 | 1189 | 0.020 |
Why?
|
| Placebos | 2 | 2002 | 1659 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2013 | 1888 | 0.020 |
Why?
|
| Antibodies, Bacterial | 2 | 2005 | 1473 | 0.020 |
Why?
|
| E-Selectin | 1 | 2010 | 576 | 0.020 |
Why?
|
| Macrocyclic Compounds | 1 | 2007 | 68 | 0.020 |
Why?
|
| Blast Crisis | 1 | 2008 | 102 | 0.020 |
Why?
|
| Calcineurin | 1 | 2008 | 233 | 0.020 |
Why?
|
| Amnesia, Anterograde | 1 | 2007 | 20 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2014 | 2196 | 0.020 |
Why?
|
| Erythroblasts | 1 | 2007 | 142 | 0.020 |
Why?
|
| Erythrocytes | 1 | 2016 | 2394 | 0.020 |
Why?
|
| Carcinoma, Small Cell | 1 | 1989 | 420 | 0.020 |
Why?
|
| Thalidomide | 1 | 2012 | 886 | 0.020 |
Why?
|
| Epitopes | 2 | 2004 | 2523 | 0.020 |
Why?
|
| Lectins, C-Type | 1 | 2010 | 592 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2016 | 3635 | 0.020 |
Why?
|
| Amino Acid Sequence | 3 | 2004 | 13398 | 0.020 |
Why?
|
| Actuarial Analysis | 2 | 2001 | 370 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2003 | 5379 | 0.020 |
Why?
|
| Diabetes Insipidus | 1 | 2007 | 143 | 0.020 |
Why?
|
| Philadelphia Chromosome | 1 | 2007 | 119 | 0.020 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2005 | 4627 | 0.020 |
Why?
|
| Drinking | 1 | 2008 | 196 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 2012 | 1171 | 0.020 |
Why?
|
| Organ Size | 1 | 2011 | 2261 | 0.020 |
Why?
|
| Cell Survival | 1 | 2016 | 5745 | 0.020 |
Why?
|
| Sacrum | 1 | 2008 | 270 | 0.020 |
Why?
|
| Sex Factors | 2 | 2011 | 10611 | 0.020 |
Why?
|
| Hepatitis C | 1 | 1996 | 1596 | 0.020 |
Why?
|
| Neutropenia | 1 | 2011 | 894 | 0.020 |
Why?
|
| Self Report | 1 | 2018 | 3768 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2010 | 1132 | 0.020 |
Why?
|
| Heterozygote | 1 | 2013 | 2796 | 0.020 |
Why?
|
| High-Throughput Screening Assays | 1 | 2012 | 938 | 0.020 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2005 | 37 | 0.020 |
Why?
|
| Carboplatin | 2 | 2002 | 787 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2014 | 2866 | 0.020 |
Why?
|
| von Willebrand Factor | 1 | 2010 | 681 | 0.020 |
Why?
|
| Canada | 1 | 2011 | 2120 | 0.020 |
Why?
|
| Proteome | 1 | 2016 | 1896 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2017 | 2969 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2009 | 792 | 0.020 |
Why?
|
| Professional Staff Committees | 1 | 2005 | 37 | 0.020 |
Why?
|
| Quality of Health Care | 2 | 2013 | 4305 | 0.020 |
Why?
|
| Phylogeny | 1 | 2013 | 2837 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 2717 | 0.020 |
Why?
|
| RNA, Neoplasm | 2 | 2003 | 745 | 0.020 |
Why?
|
| Epitope Mapping | 1 | 2006 | 300 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2011 | 3583 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2011 | 15645 | 0.020 |
Why?
|
| Lymphocytosis | 2 | 2000 | 121 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 1998 | 5531 | 0.020 |
Why?
|
| Medical Staff, Hospital | 1 | 2009 | 601 | 0.020 |
Why?
|
| Chromosome Breakage | 1 | 2005 | 159 | 0.020 |
Why?
|
| Molecular Chaperones | 1 | 2010 | 760 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2021 | 4856 | 0.020 |
Why?
|
| RNA-Binding Proteins | 2 | 2005 | 1882 | 0.020 |
Why?
|
| Cell Differentiation | 3 | 2007 | 11639 | 0.010 |
Why?
|
| Depression | 1 | 2005 | 8223 | 0.010 |
Why?
|
| Myeloid Cells | 1 | 2010 | 838 | 0.010 |
Why?
|
| Lymphatic Metastasis | 2 | 2005 | 2885 | 0.010 |
Why?
|
| Serologic Tests | 1 | 2007 | 382 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2005 | 348 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 2823 | 0.010 |
Why?
|
| Plasma Exchange | 1 | 2005 | 160 | 0.010 |
Why?
|
| Albumins | 1 | 2007 | 578 | 0.010 |
Why?
|
| Signal Transduction | 3 | 2013 | 23597 | 0.010 |
Why?
|
| Lung Neoplasms | 3 | 2005 | 13446 | 0.010 |
Why?
|
| Smoking | 1 | 2001 | 9082 | 0.010 |
Why?
|
| Self-Assessment | 1 | 2006 | 401 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 1990 | 1415 | 0.010 |
Why?
|
| Rabbits | 1 | 2010 | 4729 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2012 | 6202 | 0.010 |
Why?
|
| Health | 1 | 2006 | 397 | 0.010 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2007 | 390 | 0.010 |
Why?
|
| Observer Variation | 1 | 2009 | 2611 | 0.010 |
Why?
|
| Major Histocompatibility Complex | 1 | 2006 | 879 | 0.010 |
Why?
|
| Anti-Retroviral Agents | 1 | 2013 | 1786 | 0.010 |
Why?
|
| Intestines | 1 | 2012 | 1906 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 4342 | 0.010 |
Why?
|
| Logistic Models | 2 | 2001 | 13273 | 0.010 |
Why?
|
| U937 Cells | 1 | 2003 | 259 | 0.010 |
Why?
|
| Gene Fusion | 1 | 2005 | 357 | 0.010 |
Why?
|
| Bone Marrow Examination | 1 | 2002 | 155 | 0.010 |
Why?
|
| Registries | 1 | 2019 | 8346 | 0.010 |
Why?
|
| Pain | 2 | 2009 | 5077 | 0.010 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2003 | 201 | 0.010 |
Why?
|
| Methods | 1 | 2002 | 1061 | 0.010 |
Why?
|
| Hospitalization | 1 | 2022 | 10810 | 0.010 |
Why?
|
| Autoantibodies | 1 | 2010 | 2114 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2005 | 645 | 0.010 |
Why?
|
| Karnofsky Performance Status | 1 | 2002 | 163 | 0.010 |
Why?
|
| Interferons | 1 | 2005 | 714 | 0.010 |
Why?
|
| Tyrosine | 2 | 1997 | 1427 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2002 | 247 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 20133 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2002 | 285 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2013 | 2530 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 3796 | 0.010 |
Why?
|
| Marriage | 1 | 2003 | 351 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2009 | 4016 | 0.010 |
Why?
|
| Cyclosporine | 1 | 2003 | 777 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2002 | 298 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2008 | 2426 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 1724 | 0.010 |
Why?
|
| Focal Adhesion Kinase 2 | 1 | 2000 | 87 | 0.010 |
Why?
|
| Fibrosis | 1 | 2008 | 2073 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2007 | 1394 | 0.010 |
Why?
|
| Ascites | 1 | 2002 | 336 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2010 | 2627 | 0.010 |
Why?
|
| Body Fluids | 1 | 2002 | 320 | 0.010 |
Why?
|
| Research Design | 1 | 2016 | 6204 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2009 | 1802 | 0.010 |
Why?
|
| Musculoskeletal Diseases | 1 | 2006 | 598 | 0.010 |
Why?
|
| Immunoglobulin J Recombination Signal Sequence-Binding Protein | 1 | 2000 | 133 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2010 | 3498 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2013 | 3799 | 0.010 |
Why?
|
| Amygdala | 1 | 2007 | 1376 | 0.010 |
Why?
|
| Myocardium | 1 | 2012 | 4764 | 0.010 |
Why?
|
| Chromosome Mapping | 2 | 2001 | 4617 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2000 | 419 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2003 | 2743 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 1990 | 2248 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2012 | 36547 | 0.010 |
Why?
|
| Pneumonia, Viral | 1 | 1996 | 3231 | 0.010 |
Why?
|
| Mucin-1 | 1 | 2003 | 535 | 0.010 |
Why?
|
| Receptors, Purinergic P1 | 1 | 1998 | 108 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2003 | 1716 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2008 | 2116 | 0.010 |
Why?
|
| RNA, Messenger | 3 | 2002 | 12768 | 0.010 |
Why?
|
| Pregnancy | 2 | 2017 | 30230 | 0.010 |
Why?
|
| Testis | 1 | 2001 | 782 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 3690 | 0.010 |
Why?
|
| Thalassemia | 1 | 1998 | 267 | 0.010 |
Why?
|
| Integrin alpha4beta1 | 1 | 1997 | 119 | 0.010 |
Why?
|
| Graft vs Host Reaction | 1 | 1997 | 99 | 0.010 |
Why?
|
| Adsorption | 1 | 1997 | 198 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2008 | 3558 | 0.010 |
Why?
|
| Algorithms | 2 | 2010 | 14064 | 0.010 |
Why?
|
| Sensitivity and Specificity | 2 | 2002 | 14643 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 4163 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 2008 | 12973 | 0.010 |
Why?
|
| Calcium | 1 | 1990 | 5769 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 2002 | 1227 | 0.010 |
Why?
|
| Pneumonia | 1 | 2008 | 2158 | 0.010 |
Why?
|
| Estrogens | 1 | 2003 | 1528 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2001 | 1740 | 0.010 |
Why?
|
| Genome, Human | 1 | 2009 | 4443 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 1996 | 283 | 0.010 |
Why?
|
| Nuclear Family | 1 | 1996 | 311 | 0.010 |
Why?
|
| DNA Probes | 1 | 1996 | 541 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2007 | 2895 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2008 | 3209 | 0.010 |
Why?
|
| Consensus | 1 | 2005 | 3202 | 0.010 |
Why?
|
| Lung | 1 | 2014 | 10046 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2001 | 2510 | 0.010 |
Why?
|
| Mitoxantrone | 1 | 1995 | 148 | 0.010 |
Why?
|
| Daunorubicin | 1 | 1995 | 157 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2002 | 1726 | 0.010 |
Why?
|
| Ifosfamide | 1 | 1995 | 233 | 0.010 |
Why?
|
| Hippocampus | 1 | 2007 | 3772 | 0.010 |
Why?
|
| Ribavirin | 1 | 1996 | 395 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2003 | 2430 | 0.010 |
Why?
|
| Hydroxyurea | 1 | 1995 | 284 | 0.010 |
Why?
|
| Erythropoiesis | 1 | 1997 | 691 | 0.010 |
Why?
|
| Peptides | 1 | 2005 | 4331 | 0.010 |
Why?
|
| Etoposide | 1 | 1995 | 636 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2008 | 3743 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2003 | 2645 | 0.010 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1993 | 317 | 0.010 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1998 | 1164 | 0.010 |
Why?
|
| Reference Values | 1 | 2000 | 4909 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2005 | 2559 | 0.010 |
Why?
|
| Healthcare Disparities | 1 | 2008 | 3407 | 0.010 |
Why?
|
| DNA Primers | 1 | 1996 | 2824 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1995 | 1142 | 0.010 |
Why?
|
| Eye Enucleation | 1 | 1991 | 128 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1992 | 772 | 0.010 |
Why?
|
| Paraproteins | 1 | 1991 | 38 | 0.010 |
Why?
|
| Amphotericin B | 1 | 1991 | 140 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1992 | 765 | 0.010 |
Why?
|
| Infusion Pumps | 1 | 1991 | 163 | 0.010 |
Why?
|
| Splenectomy | 1 | 1992 | 389 | 0.010 |
Why?
|
| Eye Infections, Fungal | 1 | 1991 | 99 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2008 | 5509 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1991 | 705 | 0.010 |
Why?
|
| Hematocrit | 1 | 1991 | 622 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 20690 | 0.010 |
Why?
|
| Catheters, Indwelling | 1 | 1991 | 436 | 0.000 |
Why?
|
| Liver Neoplasms | 1 | 2005 | 4349 | 0.000 |
Why?
|
| Kidney Function Tests | 1 | 1991 | 684 | 0.000 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1990 | 241 | 0.000 |
Why?
|
| Hepatitis | 1 | 1990 | 226 | 0.000 |
Why?
|
| Cell Cycle | 1 | 1996 | 2920 | 0.000 |
Why?
|
| Herpes Zoster | 1 | 1990 | 252 | 0.000 |
Why?
|
| Cell Adhesion | 1 | 1994 | 3089 | 0.000 |
Why?
|
| Phosphoproteins | 1 | 1996 | 2444 | 0.000 |
Why?
|
| Brain | 1 | 2014 | 27179 | 0.000 |
Why?
|
| Pulmonary Fibrosis | 1 | 1990 | 503 | 0.000 |
Why?
|
| Catheterization, Central Venous | 1 | 1991 | 538 | 0.000 |
Why?
|
| Probability | 1 | 1991 | 2474 | 0.000 |
Why?
|
| Head and Neck Neoplasms | 1 | 2000 | 2924 | 0.000 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1990 | 710 | 0.000 |
Why?
|
| Lymph Nodes | 1 | 1995 | 3447 | 0.000 |
Why?
|
| Brain Neoplasms | 1 | 2005 | 9065 | 0.000 |
Why?
|
| Palliative Care | 1 | 1998 | 3640 | 0.000 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 11090 | 0.000 |
Why?
|
| Cell Line | 1 | 1991 | 15540 | 0.000 |
Why?
|